Tag Archives: BLCM

15 Biggest Mid-Day Losers For Thursday

Related Mid-Afternoon Market Update: CytomX Therapeutics Climbs Following Bristol-Myers Squibb Partnership; Medgenics Shares Slide 15 Biggest Mid-Day Losers For Monday Cerulean Pharma's (CERU) CEO Chris Guiffre on Cerulean and Dar茅 Proposed Transaction (Transcript) (Seeking Alpha) Related Mid-Afternoon Market Update: Cancer Genetics Gains After Q4 Results; Heat Biologics Shares Slide Mid-Day Market Update: Dow Rises Over 50 Points; Tandem Diabetes Care Shares Plunge Tandem Diabetes prices stock offering at $1.25; shares off 19% premarket (Seeking Alpha) Cerulean Pharma Inc (NASDAQ: CERU) shares dipped 27 percent to $0.817. Cerulean Pharma shares have dropped 60.28 percent over the past 52 weeks, while the S&P 500 index has gained 15.31 percent in the same period. Tandem Diabetes Care Inc (NASDAQ: TNDM) shares tumbled 24.2 percent to $1.17. Tandem Diabetes Care priced 18 million share offering at $1.25 per share. Alphatec Holdings Inc (NASDAQ: ATEC) shares fell 21.1 percent to $2.10 as the company reported a $18.9 million private placement. Heat Biologics Inc (NASDAQ: HTBX) shares dropped 15.5 percent to $0.870. Heat Biologics priced its 5 million share offering at $0.80 per share. Rave Restaurant Group Inc (NASDAQ: RAVE) shares fell 15 percent to $1.76. QuickLogic Corporation (NASDAQ: QUIK) shares declined 12.2 percent to $1.58. QuickLogic priced its 10 million share offering at $1.50 per share. Orion Engineered Carbons SA (NYSE: OEC) shares dropped 9.5 percent to $19.10. Orion Engineered Carbons reported a 5 million common stock secondary offering. Interpace Diagnostics Group Inc (NASDAQ: IDXG) shares fell 8.7 percent to $2.61 after the company reported debt restructuring and agreed to eliminate its royalty and milestone obligations. Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) declined 7.4 percent to $72.56 after the company reported topline data from Phase 2 UXOO7 study. The trial did not meet primary endpoint. PiperJaffray downgraded Ultragenyx Pharmaceutical from Overweight to Neutral. Proofpoint Inc (NASDAQ: PFPT) shares declined 5.1 percent to $75.13. Goldman Sachs downgraded Proofpoint from Neutral to Sell. Pulmatrix Inc (NASDAQ: PULM) shares fell 5.1 percent to $3.70 after rising 0.52 percent on Wednesday. Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) fell 4.5 percent to $13.73. Bellicum Pharmaceuticals reported a proposed public offering of 5 million shares of common stock. Cherry Hill Mortgage Investment Corp (NYSE: CHMI) declined 4.2 percent to $17.60 as the company reported a 4.5 million share offering. Merit Medical Systems, Inc. (NASDAQ: MMSI) declined 4 percent to $28.42. Merit Medical priced 4.5 million share public offering of common stock at $28.25 per share. Centene Corp (NYSE: CNC) shares fell 3.2 percent to $65.86. Citi downgraded Centene from Buy to Neutral. Latest Ratings for CERU

Aug 2016 Barclays Maintains Overweight
Aug 2016 JMP Securities Downgrades Market Perform Market Perform
Aug 2016 Janney Capital Downgrades Buy Neutral

View More Analyst Ratings for CERU
View the Latest Analyst Ratings

Juno Therapeutics Q4 Earnings Report: What to Expect?

The Q4 2016 earnings report of mid cap cancer stock Juno Therapeutics Inc(NASDAQ: JUNO) is scheduled for after the market closes onWednesday (March 1st).Juno Therapeutics was inour SmallCap Network Elite Opportunity (SCN EO) portfolio in the past because thecompanywas well capitalized and had promising novel cellular immunotherapies based platforms (Immunotherapy involves engineering a patient’s cells and then infusing them back into the body to boost the immune system and better fight cancer with less side effects than radiation). A pullbackhad also madesharestechnically attractive for traders at the time.However and last November, Juno Therapeutics lost nearly a quarter of its value after two patients enrolled in its cancer trial died -prompting the Company to place the trial on hold.

A technical chart for small cap Juno Therapeutics shows downtrending lines, but shares have been breaking a bit higher from a December bottom:

A long term performance shows shares of small cap cancer stocks Juno Therapeutics and Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) underperforming whileKite Pharma Inc (NASDAQ: KITE)andlarge cap Celgene Corporation (NASDAQ: CELG) have performed better:

Back in November, Juno Therapeutics reported third quarter revenue of $20.8 million versus $1.6 million due primarily to revenue recognized in connection with the Celgene collaboration and CD19 opt-in. The net losswas $56.9 million versus$23.2 million. Cash, cash equivalents, and marketable securities as of September 30, 2016 were $1.04 billion compared to $1.11 billion as of June 30, 2016 and $1.22 billion as of December 31, 2015. The CEO commented:

JCAR017, a key product candidate of our CD19 platform, has shown encouraging preliminary efficacy and safety results in NHL and pediatric ALL. At the upcoming American Society of Hematology meeting, additional data from our Phase I trial for JCAR017 in NHL patients will be presented. Progress with CAR T therapy continues as we strive to bring these innovative product candidates to patients battling cancer. We look forward to the upcoming presentations at ASH, including 11 total presentations from a number of ongoing and completed studies.

Finally, here is a quick recap ofmid cap Juno Therapeutics recent earnings history along with EPS estimate trends from the Yahoo! Finance analyst estimates page:

EPS Est. -0.45 -0.52 -0.41 -0.55
EPS Actual -0.53 -0.78 -0.64 -0.57
Difference -0.08 -0.26 -0.23 -0.02
Surprise % -17.80% -50.00% -56.10% -3.60%
EPS TrendCurrent Qtr. (Dec 2016)Next Qtr. (Mar 2017)Current YearNext Year
Current Estimate -0.61 -0.8 -2.6 -2.82
7 Days Ago -0.61 -0.8 -2.6 -2.82
30 Days Ago -0.63 -0.82 -2.6 -2.84
60 Days Ago -0.63 -0.82 -2.6 -2.84
90 Days Ago -0.62 -0.83 -2.54 -2.72

Do you like this trading idea and want more trading setups delivered to you every day? Consider investing in a subscription to our SmallCap Network Elite Opportunity (SCN EO) portfolio newsletter or our Under the Radar Movers newsletter where you’ll get more and even better trading setups, investing ideas or tips.